Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Bryan Irving, Ph.D.

Vice President, Cancer Immunology at CytomX Therapeutics


Dr. Irving’s research has focused primarily on exploring ways to modulate T cell activity for therapeutic benefit in both autoimmune and oncology settings. His doctoral work, performed in the lab of Art Weiss at University of CA. San Francisco, pioneered the single-chain chimeric antigen receptor (CAR) technology now being used in patient’s T cells to treat hematologic malignancies. Following post-doctoral work performed at Harvard and UCSF, he joined Genentech in 2001, where for 12 years his research focused in both areas of Inflammation and Immune Oncology.  Among his most notable contributions at Genentech, was his principle inventorship and research leadership of atezolizumab (Tecentriq), now approved for the treatment of bladder and lung cancers.  He is currently Vice President of Cancer Immunology at CytomX Therapeutics leading efforts to generate protease-activatable immunotherapies designed to mobilize anti-tumor immunity locally in the tumor microenvironment.

Dr. Irving earned his B.A at University of California, Berkeley and Ph.D in Immunology at University of California, San Francisco.